Stem Cell Factor Antibody: Effective Manipulation of Antihormonal Therapy in Resistant Human Breast Cancer In Vitro

Khalid Bahram Arif, Issam Hussain, Carol Rea, Mohamed El-Sheemy


However, the use of Tamoxifen is limited by intrinsic and acquired resistance, which may be associated with the de-regulation of the kinase protein expression or an increase in multiple drug resistance (MDR) expression. Two breast cancer cell lines, wild type MCF7 WT (sensitive, i.e., ER+) and MDA-MB-231 (resistant, i.e., ER-), were used. Expression of P-glycoprotein (Pgp) was measured, the cells were treated with 4- hydroxy tamoxifen in the presence or absence of anti-stem cell factor, apoptosis protein (Annexin V) was measured and Influx/efflux rates were monitored by using Technetium99m methoxyisobutylisonitrile (99m Tc-Sestamibi-MIBI) at different time intervals. Results showed positive expression of AnnexinV in MDA-MB-231 and MCF7/WT, and the effect of blocking of the stem cell factor showed an increase in the drug accumulation within the MDA-MB-231 cell line. In conclusion, this study showed that the anti-stem cell factor enhances the effectiveness of antihormonal therapies determined by 99m Tc-MIBI. These findings may have implications for the use of anti-stem cell factor with anti-hormonal therapy in ER-negative breast cancer in order to overcome drug resistance and improve the outcome.


Antibody, Antihormonal therapy, Human breast cancer

Full Text:

 Subscribers Only



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.